ABCL vs RXRX: which is the better buy in 2026?
On Alexandria's Compass, AbCellera Biologics Inc. has the edge with a 89/100 score versus 88/100 for RXRX. Here is how they stack up, factor by factor.
AbCellera Biologics Inc.
NASDAQ:ABCL
Antibody discovery factory pivoting to owning the drugs it finds, with two Phase 1/2 readouts that could re-rate the whole thesis.
Full ABCL analysisRecursion Pharmaceuticals
NASDAQ:RXRX
Recursion's AI drug discovery platform is real science, but $208M annual cash burn against a $1.9B market cap demands clinical proof soon.
Full RXRX analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is ABCL or RXRX the better buy in 2026?
By Compass Score, AbCellera Biologics Inc. (NASDAQ:ABCL) edges it at 89/100 versus 88/100 for RXRX. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare ABCL and RXRX?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.